[go: up one dir, main page]

EP1001764A4 - Heterozyklische amide als zelladhäsionshemmern - Google Patents

Heterozyklische amide als zelladhäsionshemmern

Info

Publication number
EP1001764A4
EP1001764A4 EP98926122A EP98926122A EP1001764A4 EP 1001764 A4 EP1001764 A4 EP 1001764A4 EP 98926122 A EP98926122 A EP 98926122A EP 98926122 A EP98926122 A EP 98926122A EP 1001764 A4 EP1001764 A4 EP 1001764A4
Authority
EP
European Patent Office
Prior art keywords
cell adhesion
adhesion inhibitors
heterocyclic amides
amides
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98926122A
Other languages
English (en)
French (fr)
Other versions
EP1001764A1 (de
Inventor
Philippe L Durette
William K Hagmann
Malcolm Maccoss
Sander G Mills
Richard A Mumford
Gail M Van Riper
Jack A Schmidt
Nancy J Kevin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714314.3A external-priority patent/GB9714314D0/en
Priority claimed from GBGB9800686.9A external-priority patent/GB9800686D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1001764A1 publication Critical patent/EP1001764A1/de
Publication of EP1001764A4 publication Critical patent/EP1001764A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP98926122A 1997-05-29 1998-05-29 Heterozyklische amide als zelladhäsionshemmern Ceased EP1001764A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US4801797P 1997-05-29 1997-05-29
US48017P 1997-05-29
GB9714314 1997-07-07
GBGB9714314.3A GB9714314D0 (en) 1997-07-07 1997-07-07 Heterocyclic amide compounds as cell adhesion inhibitors
US6652597P 1997-11-25 1997-11-25
US66525P 1997-11-25
GB9800686 1998-01-14
GBGB9800686.9A GB9800686D0 (en) 1998-01-14 1998-01-14 Hetrocyclic amide compounds as cell adhesion inhibitors
PCT/US1998/010940 WO1998053814A1 (en) 1997-05-29 1998-05-29 Heterocyclic amide compounds as cell adhesion inhibitors

Publications (2)

Publication Number Publication Date
EP1001764A1 EP1001764A1 (de) 2000-05-24
EP1001764A4 true EP1001764A4 (de) 2005-08-24

Family

ID=27451676

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98926122A Ceased EP1001764A4 (de) 1997-05-29 1998-05-29 Heterozyklische amide als zelladhäsionshemmern

Country Status (4)

Country Link
EP (1) EP1001764A4 (de)
JP (1) JP2002512625A (de)
CA (1) CA2291778A1 (de)
WO (1) WO1998053814A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
DE69833654T2 (de) * 1997-05-29 2006-12-14 Merck & Co., Inc. (A New Jersey Corp.) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
ATE249421T1 (de) 1997-06-23 2003-09-15 Tanabe Seiyaku Co Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
JP2001524465A (ja) * 1997-11-24 2001-12-04 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害剤としての置換β−アラニン誘導体
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JP2002504534A (ja) 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド α４インテグリンの阻害剤としてのフェニルアラニン誘導体
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6218423B1 (en) * 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
BR0007663A (pt) 1999-01-22 2002-05-07 Elan Pharm Inc Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
CA2359114A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1213025C (zh) 1999-02-18 2005-08-03 霍夫曼-拉罗奇有限公司 硫代酰胺衍生物
DK1154987T3 (da) * 1999-02-18 2004-08-09 Hoffmann La Roche Phenylalaninolderivater
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
JP2003503350A (ja) * 1999-06-30 2003-01-28 第一製薬株式会社 Ｖｌａ−４インヒビター化合物
RU2264386C2 (ru) * 1999-06-30 2005-11-20 Дайити Фармасьютикал Ко., Лтд. Соединения ингибиторы vla-4
WO2001012186A1 (en) 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
US6420418B1 (en) 1999-08-16 2002-07-16 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
EP1088821A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
CA2392566A1 (en) * 1999-12-06 2001-06-14 F. Hoffmann-La Roche Ag 4-pyridinyl-n-acyl-l-phenylalanines
RU2266901C2 (ru) * 1999-12-06 2005-12-27 Ф.Хоффманн-Ля Рош Аг 4-пиримидинил-n-ацил-l-фенилаланины и фармацевтическая композиция
NZ519447A (en) 1999-12-16 2004-03-26 Biogen Inc Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
IL149758A0 (en) 1999-12-28 2002-11-10 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
EP1253923A1 (de) * 2000-01-28 2002-11-06 Biogen, Inc. Pharmazeutische zusammensetzungen enthaltend anti- beta 1 integrin verbindungen und verwendung
WO2001068586A2 (en) * 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
EP1332132B1 (de) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
JP2004516237A (ja) 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのピペリジンアミド類
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
EP1193268A1 (de) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch aktive Sulfonamidderivate mit sowohl lipophilen als auch ionisierbaren Gruppen als Inhibitoren von Protein-JunKinasen
EP1193267A1 (de) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksame hydrophile Sulfonamidderivate zur Verwendung als Proteinjunkinasehemmer
EP1323711B1 (de) * 2000-09-29 2006-11-15 Ajinomoto Co., Inc. Neue phenylalanin-derivate
US6855708B2 (en) 2001-03-20 2005-02-15 Merck & Co., Inc. N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
JP2004526733A (ja) 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド 強力な細胞接着阻害剤としての置換ｎ−アリールスルホニル−プロリン誘導体
US6559174B2 (en) 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
PL373156A1 (en) * 2001-12-14 2005-08-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
WO2004005262A2 (en) 2002-07-02 2004-01-15 Schering Corporation New neuropeptide y y5 receptor antagonists
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
WO2004041279A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
WO2004066931A2 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1626957A1 (de) 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Azabicycloderivative als muscarinrezeptorantagonisten
EP1654261B1 (de) 2003-05-21 2007-11-14 Boehringer Ingelheim International GmbH Verbindungen als hepatitis c inhibitoren
WO2005000244A2 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
WO2005070921A1 (en) * 2004-01-23 2005-08-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
AU2005234596B8 (en) 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
CA2561858A1 (en) * 2004-04-20 2005-12-15 Amgen Inc. Arylsulfonamides and uses related thereto
US7777042B2 (en) 2004-06-29 2010-08-17 Aventis Pharmaceuticals Inc. N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof
EP1778637B1 (de) * 2004-06-29 2012-02-22 Aventis Pharmaceuticals Inc. FKBP bindende Zusammensetzung und deren pharmazeutische Verwendung
EA012433B1 (ru) * 2004-07-08 2009-10-30 Элан Фармасьютикалз, Инк. Многовалентные vla-4 антагонисты, содержащие полимерные фрагменты
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
WO2006007708A1 (en) 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
US7618983B2 (en) 2004-11-10 2009-11-17 Janssen Pharmaceutica, N.V. Bicyclic triazole α4 integrin inhibitors
ZA200803016B (en) 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
ATE493405T1 (de) 2005-09-29 2011-01-15 Elan Pharm Inc Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
WO2007101165A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
NZ589086A (en) 2008-04-11 2012-09-28 Merrimack Pharmaceuticals Inc Human serum albumin (HSA) linkers and conjugates thereof
EA020470B1 (ru) 2008-11-26 2014-11-28 Пфайзер Инк. 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
US20100204221A1 (en) 2009-02-09 2010-08-12 Hariprasad Vankayalapati Pyrrolopyrimidinyl axl kinase inhibitors
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
KR20210128024A (ko) * 2014-12-12 2021-10-25 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 알파9 인테그린 길항제를 사용한 골수 줄기 세포 니치로부터의 hsc의 이탈 및 방출
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
EP3436046A4 (de) * 2016-04-01 2020-03-11 The Regents of The University of California Inhibitoren von integrin alpha 5 beta 1 und verfahren zur verwendung
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
CN109111435B (zh) * 2017-06-26 2022-03-18 南京柯菲平盛辉制药有限公司 一类吡咯烷磺酰基衍生物RORγ调节剂及其用途
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
LT3873884T (lt) 2018-10-30 2025-03-10 Gilead Sciences, Inc. 3-(chinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diono dariniai kaip alfa4beta7 integrino inhibitoriai, skirti uždegiminių ligų gydymui
EP3873897B1 (de) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanin-derivate als alpha4beta7 integrin-inhibitoren zur behandlung von entzündlichen erkrankungen
PL3873900T3 (pl) 2018-10-30 2025-06-02 Gilead Sciences, Inc. Imidazo[1,2-a]pirydynowe pochodne jako inhibitory integryny alpha4beta7 do leczenia chorób zapalnych
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
EP4013499A1 (de) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Verbindungen zur inhibierung von alpha-4-beta-7-integrin
JP7620649B2 (ja) 2020-06-10 2025-01-23 アリゴス セラピューティクス インコーポレイテッド コロナウイルス、ピコルナウイルス及びノロウイルス感染を治療するための抗ウイルス化合物
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350698A (en) * 1981-09-25 1982-09-21 Smithkline Corporation Antiallergic imidosulfamides
EP0443132A1 (de) * 1989-12-22 1991-08-28 Fujisawa Pharmaceutical Co., Ltd. Peptide mit tachykininantagonistischer Aktivität, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
EP0696593A2 (de) * 1994-08-11 1996-02-14 Bristol-Myers Squibb Company Inhibitoren der farnesyl protein Transferase
WO1996040641A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Sulfonamide derivatives as cell adhesion modulators
WO1997021690A1 (en) * 1995-11-28 1997-06-19 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IT1244873B (it) * 1990-09-12 1994-09-12 Depha Team Srl Derivati dell'acido 5-aminosalicilico (5-asa) per la terapia delle infiammazioni croniche intestinali
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
CA2118985A1 (en) * 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350698A (en) * 1981-09-25 1982-09-21 Smithkline Corporation Antiallergic imidosulfamides
EP0443132A1 (de) * 1989-12-22 1991-08-28 Fujisawa Pharmaceutical Co., Ltd. Peptide mit tachykininantagonistischer Aktivität, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
EP0696593A2 (de) * 1994-08-11 1996-02-14 Bristol-Myers Squibb Company Inhibitoren der farnesyl protein Transferase
WO1996040641A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Sulfonamide derivatives as cell adhesion modulators
WO1997021690A1 (en) * 1995-11-28 1997-06-19 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BYK G ET AL: "Local constrained shifty pseudopeptides inhibitors of ras-farnesyl transferase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 22, 16 November 1995 (1995-11-16), pages 2677 - 2682, XP004135213, ISSN: 0960-894X *
CALCAGNI A ET AL: "Peptides containing the sulfonamide junction: Synthesis, structure, and conformation of Z-Tau-Pro-Phe-NHiPr", BIOPOLYMERS 1997 UNITED STATES, vol. 41, no. 5, 1997, pages 555 - 567, XP002332346, ISSN: 0006-3525 *
HAGMANN W K ET AL: "The discovery of sulfonylated dipeptides as Potent VLA-4 antagonists", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 22 OCT 2001 UNITED KINGDOM, vol. 11, no. 20, 22 October 2001 (2001-10-22), pages 2709 - 2713, XP002332349, ISSN: 0960-894X *
LIN L S ET AL: "Specific and dual antagonists of [alpha]4[beta]1 and [alpha]4[beta]7 integrins", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 21 JAN 2002 UNITED KINGDOM, vol. 12, no. 2, 21 January 2002 (2002-01-21), pages 133 - 136, XP002332347, ISSN: 0960-894X *
LIN L S ET AL: "The discovery of acylated [beta]-amino acids as potent and orally bioavailable VLA-4 antagonists", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 25 FEB 2002 UNITED KINGDOM, vol. 12, no. 4, 25 February 2002 (2002-02-25), pages 611 - 614, XP002332348, ISSN: 0960-894X *
See also references of WO9853814A1 *

Also Published As

Publication number Publication date
JP2002512625A (ja) 2002-04-23
WO1998053814A1 (en) 1998-12-03
CA2291778A1 (en) 1998-12-03
EP1001764A1 (de) 2000-05-24

Similar Documents

Publication Publication Date Title
EP1001764A4 (de) Heterozyklische amide als zelladhäsionshemmern
DE69716615D1 (de) Heterozyklische metalloproteaseinhibitoren
ATE330935T1 (de) Inhibitoren der alpha4 vermittelten zelladhäsion
DE69637328D1 (de) Zelladhäsionsinhibitoren
AU8059598A (en) Heterocyclic amide compounds as cell adhesion inhibitors
DK0925287T3 (da) Heterocykliske metalloproteaseinhibitorer
NO20000226L (no) Nye spiroazabicykliske heterocykliske forbindelser
EE200000610A (et) p38 heterotsüklilised inhibiitorid
FI951001L (fi) Sulfatoituja alfa-glykolipidijohdannaisia soluadheesioinhibiittoreina
DE59703869D1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
AU6903200A (en) Heterocycle amides as cell adhesion inhibitors
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
DE60008527D1 (de) Zellproliferation inhibitoren
DE69811223D1 (de) N-triazolyl-2-indolcarbonsäureamide und ihre verwendung als cck-a agonisten
ATE269349T1 (de) Derivativen von monosacchariden als zelladhäsionshemmer
GB0017279D0 (en) Amides as cell adhesion inhibitors
DE60005300D1 (de) 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion-inhibitoren
AU1176299A (en) Tryptase inhibitors comprising heterocyclic amide compounds
FI951002A7 (fi) Sulfatoituja beta-glykolipidijohdannaisia soluadheesioinhibiittoreina
FI955818L (fi) Uudet heterosykliset amidit
GB9714314D0 (en) Heterocyclic amide compounds as cell adhesion inhibitors
GB9800686D0 (en) Hetrocyclic amide compounds as cell adhesion inhibitors
FI941265A7 (fi) Heterosyklisiä sulfoniamidotrombiini-inhibiittoreita
NO940997D0 (no) Guanidinyl-substituerte heterocykliske trombin-inhibitorer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991229

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 43/00 B

Ipc: 7A 61K 31/404 B

Ipc: 7C 07F 9/02 A

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/445 B

Ipc: 7A 61K 31/435 B

Ipc: 7A 61K 31/425 B

Ipc: 7A 61K 31/415 B

Ipc: 7A 61K 31/41 B

Ipc: 7A 61K 31/395 B

Ipc: 7A 61K 31/405 B

Ipc: 7C 07F 9/02 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050711

17Q First examination report despatched

Effective date: 20051007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20081004